Image Alternative Text

Lead with liquid Lead with Guardant360® CDx

THE ANSWERS ARE IN OUR BLOOD

checklist
Guideline-complete genomic results across all solid tumors.
FDA-Approved
The first FDA-approved comprehensive liquid biopsy.
7days
Receive comprehensive genomic results in just 7 days.

Guide appropriate treatment for more newly diagnosed NSCLC patients.*

In the NILE study, a prospective, head-to-head study of 282 patients, leading with Guardant360 LDT detected 20% more patients with biomarkers than leading with tissue testing.24  

*Disclaimer: This content has not been reviewed by the FDA. Data shown for the performance of Guardant360® Laboratory Developed Test (LDT) does not convey the performance of Guardant360 CDx.
20% more patients with biomarkers detected using Guardant360 first. 20% more patients with biomarkers detected using Guardant360 first.
Learn About
Using Guardant360 CDx in your practice 
See The Data
View clinical evidence* 
*Disclaimer: This content has not been reviewed by the FDA. Data shown for the performance of Guardant360® Laboratory Developed Test (LDT) does not convey the performance of Guardant360 CDx.